Evidence map›Paper›PMID 34158420›Full record

ArticleJournal of obesity & metabolic syndrome2021

Obesity Fact Sheet in Korea, 2020: Prevalence of Obesity by Obesity Class from 2009 to 2018.

Ga Eun Nam, Yang-Hyun Kim, Kyungdo Han, Jin-Hyung Jung, Eun-Jung Rhee, Won-Young Lee, Obesity Fact Sheet of the Korean Society for the Study of Obesity

Registry-linked trialAbstract read
In one paragraph

Article in Journal of obesity & metabolic syndrome, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05869799 (Effect of Vigiis 101 Lactic Acid Bacteria Powder on Body Weight and Body Fat in Overweight Participants), which is not on this map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05869799 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Effect of Vigiis 101 Lactic Acid Bacteria Powder on Body Weight and Body Fat in Overweight Participants: a Randomized, Double-blinded, Placebo-controlled Trial

TypeinterventionalSponsorSunWay Biotech Co., LTD.Ran2023 to 2025Enrolled100ConditionsBody Weight, Body Fat, OverweightArmsVigiis 101 Lactobacillus Capsules, Placebo Capsules
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Efficacy and Safety ofFrontiers in endocrinology · 2021
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Anti-Obesity Effects ofInternational journal of molecular sciences · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Effects ofNutrition research and practice · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ga Eun NamDepartment of Family Medicine, Korea University College of Medicine, Seoul, Korea.
Yang-Hyun KimDepartment of Family Medicine, Korea University College of Medicine, Seoul, Korea.
Kyungdo HanDepartment of Statistics and Actuarial Science, Soongsil University, Seoul, Korea.
Jin-Hyung JungDepartment of Biostatistics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Eun-Jung RheeDivision of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Won-Young LeeDivision of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-1082-7592
Obesity Fact Sheet of the Korean Society for the Study of Obesity

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe examined the prevalence of different obesity classes in South Korea based on the 2020 Obesity Fact Sheet.

methodsIndividuals ≥20 years who underwent a health examination provided by the Korean National Health Insurance System between 2009 and 2018 were included and the prevalence of class I, II, and III obesity was calculated for the total sample and age, sex, and region subgroups.

resultsFrom 2009 to 2018, the prevalence of all obesity classes increased across all sex and age groups and all regions. In the study population as a whole, the prevalence of class I, II, and III obesity was 29.1%, 3.2%, and 0.3% in 2009 and 32.5%, 5.2%, and 0.81% in 2018, respectively. Among young-aged individuals, the prevalence of each obesity class was 23.7%, 3.6%, and 0.44% in 2009 and 28.3%, 6.9%, and 1.61% in 2018, respectively. The prevalence among middle-aged individuals was 31.6%, 3.1%, and 0.24% in 2009 and 33.6%, 4.8%, and 0.59% in 2018; and among elderly individuals was 31.9%, 3.1%, and 0.21% in 2009 and 35.5%, 3.9%, and 0.32% in 2018. The increase in the prevalence of all obesity classes among young adults was dramatic. In particular, the class III obesity prevalence increased up to 3.8- and 3.5-fold between 2009 and 2018 in young men and women.

conclusionBased on the 2020 Obesity Fact Sheet, there was a dramatic increase in the prevalence of class II and III obesity from 2009 to 2018 among young adults, as well as the population as a whole. Optimal strategies for the prevention and treatment of obesity are needed considering the recent obesity epidemic in South Korea.

Indexed as

Fact sheetNational Health Insurance SystemObesityObesity classPrevalence

Identifiers

PMID34158420
PMCPMC8277583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.